Ioannis Alexiou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ioannis Alexiou has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Christos Liaskos
Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
1 shared publication - Ian C. Chikanza
Faculty of Medicine, Catholic University, Harare, Zimbabwe
1 shared publication - Lazaros I. Sakkas
Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
1 shared publication - Theodora Simopoulou
Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
1 shared publication
Latest Publications
- Open Access
- 2 July 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (8) , 3139-3151
Stem cell therapy in systemic sclerosis
Systemic sclerosis is a complex autoimmune disease with widespread fibrosis in skin and internal organs, microvasculopathy, and autoantibodies. The disease causes ischemic changes and leads to impairment of internal organs with reduced quality of life and life expectancy. The pathogenesis is not clearly known but involves adaptive and innate immune cells which infiltrate skin lesions mostly early in the disease process. Current treatment is based on immunosuppressives, but there is a significant unmet therapeutic need, and a new therapeutic approach is required. Autologous haematopoietic stem cell transplantation appears to be an effective therapeutic option for SSc but requires standardization to reduce transplant-related mortality and post-transplant adverse effects. Mesenchymal stem cells (MSCs), exerting immunosuppressive, antifibrotic, and angiogenic actions, appear to be a promising therapeutic option but require further refinement. MSC-derived microvesicles retain MSC functions and circumvent some of the MSC challenges and thus may provide a more favorable therapeutic approach. Key Points• There are unmet therapeutic needs for systemic sclerosis.• Autologous haematopoietic stem cell transplantation is an effective therapeutic option but needs standarization.• Mesenchymal stem cells are a promising therapeutic option but requires refinement.
- 2 July 2025
- Published by Springer Nature in Clinical Rheumatology
- Vol. 44 (8) , 3139-3151
Open AccessStem cell therapy in systemic sclerosis
Systemic sclerosis is a complex autoimmune disease with widespread fibrosis in skin and internal organs, microvasculopathy, and autoantibodies. The disease causes ischemic changes and leads to impairment of internal organs with reduced quality of life and life expectancy. The pathogenesis is not clearly known but involves adaptive and innate immune cells which infiltrate skin lesions mostly early in the disease process. Current treatment is based on immunosuppressives, but there is a significant unmet therapeutic need, and a new therapeutic approach is required. Autologous haematopoietic stem cell transplantation appears to be an effective therapeutic option for SSc but requires standardization to reduce transplant-related mortality and post-transplant adverse effects. Mesenchymal stem cells (MSCs), exerting immunosuppressive, antifibrotic, and angiogenic actions, appear to be a promising therapeutic option but require further refinement. MSC-derived microvesicles retain MSC functions and circumvent some of the MSC challenges and thus may provide a more favorable therapeutic approach. Key Points• There are unmet therapeutic needs for systemic sclerosis.• Autologous haematopoietic stem cell transplantation is an effective therapeutic option but needs standarization.• Mesenchymal stem cells are a promising therapeutic option but requires refinement.